NCT Number: NCT03460119
The aim of this study was to describe the changes in respiratory rate, heart rate and dyspnea, before and after using HFNC in patients presenting to our emergency department with ARF.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
A retrospective cohort study was performed. To all adults presenting to the emergency department who used high flow nasal cannula to treat clinical signs of acute respiratory failure based on the presence of a breathing frequency ≥ 25 breath/min and increase work of breathing evidence by dyspnea, in-drawing, accessory-muscle use and/or diaphoresis despite conventional oxygen therapy ≥ 6 l/min. Demographic variables and clinical and gasometric parameters before and after two hours using HFNC were recorded.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The high flow device that we used was an air oxygen blender (Whisper FlowⓇ), which allows FiO2 adjustment between 0.30 and 1.0 and can deliver a gas flow from 10 to 150 l/min. The gas mixture was routed from a heated humidifier (MR850 with MR 290 chamber) through a one line heated inspiratory circuit (RT241) to the subject at a temperature of 37°C via a nasal cannula (OptiflowⓇ).
Time frame: 2 hours
The closest value of Heart Rate before starting HFNC, and two hours later was collected from the electronic clinical history.
Time frame: 2 hours
The closest value of Respiratory Rate before starting HFNC, and two hours later was collected from the electronic clinical history.
Time frame: 2 hours
The closest value of Dyspnea (Modified Borg Dyspnea scale) before starting HFNC, and two hours later was collected from the electronic clinical history. The Modified Borg Dyspnea Scale is a rated numerical score used to measure dyspnea. This scale has a minimum value of 0 ( represent no dyspnea) and a maximum value of 10 (worse dyspnea).
Time frame: 2 hours
The gas flow rate and the fraction of inspired oxygen at the HFNC initiation of treatment were collected from the electronic clinical history.
Time frame: 3 minutes
Presence of a breathing frequency ≥ 25 breath/min and increase work of breathing evidence by dyspnea, in-drawing, accessory-muscle use and/or diaphoresis despite conventional oxygen therapy ≥ 6 l/min.
Time frame: until 28 days
The total hours of use of HFNC were collected from the electronic clinical history.
Time frame: until 24hs
The hours between the admission to HFNC initiation were collected from the electronic clinical history.
Time frame: 28 days
When the patient did not need for escalation to other non-invasive or invasive ventilatory support.
Time frame: 28 days
When the patient need non-invasive or invasive ventilatory support or died. The type of ventilatory support post-failure were collected from the electronic clinical history.
Time frame: 28 days
The number of patients who died after requiring HFNCO were collected from the electronic clinical history
Time frame: 28 days
Consensus between patient and/or patient´s family and the physician about the care for the terminally ill patient, provided by an organized health service
Hospital Italiano de Buenos Aires
Other
Use of High-Flow Nasal Cannula for Acute Respiratory Failure in the Emergency Department
Acronym: HFNC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04791241
Acute Respiratory Failure, COVID-19
Annecy, France
View Trial DetailsNCT04119505
Acute Respiratory Failure, Disease Attributes
Montpellier, France
View Trial DetailsNCT06441760
Acute Respiratory Failure, Cardiopulmonary Arrest
Los Angeles, California, United States
View Trial DetailsNCT06876168
Acute Respiratory Failure, Infections
Lexington, Kentucky, United States
View Trial Details